How Much Glucagon Is in Retatrutide? A Peptide Selection Guide
Published: July 18, 2026 15:21
Author: Jean Edwards
Abstract: Retatrutide, a novel triple agonist, contains no standalone glucagon; its glucagon receptor activity is integrated via a balanced GIP/GLP-1/glucagon receptor co-agonism ratio (approx. 4:1:1). Market trends show rising demand for multi-target peptides over single agonists. Compared to semaglutide and tirzepatide, retatrutide offers superior weight loss (up to 24% in trials) but higher gastrointestinal side effects. Key selection criteria include purity (>98% by HPLC), third-party COA certification, and cold-chain logistics (2-8°C). Industry data indicates a 15% CAGR for multi-agonist peptides, with regulatory compliance (GMP, ISO) being critical for brand trust.